Overview Dividends

(KYMR) Kymera Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5015751044

IRAK4, STAT6, TYK2, Protein Degradation

KYMR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -34.10%
EPS Trend (3Y Correlation): -32.1%

KYMR Revenue

Revenue Growth (3Y CAGR): 6.90%
Revenue Trend (3Y Correlation): -1.4%

Description: KYMR Kymera Therapeutics November 08, 2025

Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biotech that designs small-molecule degraders-often called PROTACs-to harness the body’s ubiquitin-proteasome system and eliminate disease-causing proteins.

The company’s lead pipeline centers on an IRAK4 inhibitor currently in a Phase II trial for hidradenitis suppurativa and atopic dermatitis, with a second STAT6-targeted candidate for type 2 inflammatory disorders and a TYK2 program aimed at broader autoimmune indications.

Kymera has a strategic alliance with Sanofi that provides an upfront payment of roughly $50 million and up to $300 million in milestone potential for non-oncology IRAK4 programs, giving the firm a non-dilutive cash infusion and validation of its degrader platform.

As of the latest 10-Q, Kymera reported cash and equivalents of about $200 million, supporting roughly 18 months of runway at its current burn rate of $70 million per year; the biotech sector’s R&D spend is growing at a 9 % CAGR, while the global targeted protein degradation market is projected to expand at ~14 % CAGR through 2030, underscoring a favorable macro backdrop for Kymera’s technology.

For a deeper quantitative view, the ValueRay platform offers a granular breakdown of KYMR’s valuation metrics and comparable peer analysis.

KYMR Stock Overview

Market Cap in USD	4,393m
Sub-Industry	Biotechnology
IPO / Inception	2020-08-21

KYMR Stock Ratings

Growth Rating	45.3%
Fundamental	29.4%
Dividend Rating	-
Return 12m vs S&P 500	-0.24%
Analyst Rating	4.55 of 5

KYMR Dividends

Currently no dividends paid

KYMR Growth Ratios

Growth Correlation 3m	93.5%
Growth Correlation 12m	43.6%
Growth Correlation 5y	-19.4%
CAGR 5y	24.08%
CAGR/Max DD 3y (Calmar Ratio)	0.34
CAGR/Mean DD 3y (Pain Ratio)	1.02
Sharpe Ratio 12m	0.39
Alpha	-11.98
Beta	2.270
Volatility	67.71%
Current Volume	600k
Average Volume 20d	698.4k
Stop Loss	55 (-6.2%)
Signal	0.50

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-275.4m TTM) > 0 and > 6% of Revenue (6% = 2.68m TTM)

FCFTA -0.22 (>2.0%) and ΔFCFTA -5.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 1433 % (prev 523.2%; Δ 910.0pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.22 (>3.0%) and CFO -251.0m > Net Income -275.4m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (80.4m) change vs 12m ago 10.12% (target <= -2.0% for YES)

Gross Margin 81.87% (prev 94.17%; Δ -12.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 4.57% (prev 10.72%; Δ -6.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -954.1 (EBITDA TTM -277.2m / Interest Expense TTM 299.0k) >= 6 (WARN >= 3)

Altman Z'' -6.73

(A) 0.57 = (Total Current Assets 728.3m - Total Current Liabilities 87.5m) / Total Assets 1.13b

(B) -0.79 = Retained Earnings (Balance) -896.8m / Total Assets 1.13b

(D) -5.62 = Book Value of Equity -896.5m / Total Liabilities 159.6m

Total Rating: -6.73 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.37

1. Piotroski 0.0pt = -5.0

2. FCF Yield -6.63% = -3.32

3. FCF Margin data missing

4. Debt/Equity 0.09 = 2.50

5. Debt/Ebitda 0.90 = 1.90

6. ROIC - WACC (= -39.96)% = -12.50

7. RoE -31.60% = -2.50

8. Rev. Trend -1.35% = -0.10

9. EPS Trend -32.06% = -1.60

What is the price of KYMR shares?

As of November 10, 2025, the stock is trading at USD 58.66 with a total of 600,026 shares traded.
Over the past week, the price has changed by -1.77%, over one month by +2.88%, over three months by +55.68% and over the past year by +13.16%.

Is Kymera Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Kymera Therapeutics (NASDAQ:KYMR) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.37 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of KYMR is around 48.80 USD . This means that KYMR is currently overvalued and has a potential downside of -16.81%.

Is KYMR a buy, sell or hold?

Kymera Therapeutics has received a consensus analysts rating of 4.55. Therefore, it is recommended to buy KYMR.

Strong Buy: 14
Buy: 3
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the KYMR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	68.2	16.3%
Analysts Target Price	68.2	16.3%
ValueRay Target Price	57.2	-2.6%

KYMR Fundamental Data Overview November 01, 2025

Market Cap USD = 4.39b (4.39b USD * 1.0 USD.USD)
P/S = 98.249
P/B = 4.1214
Beta = 2.27
Revenue TTM = 44.7m USD
EBIT TTM = -285.3m USD
EBITDA TTM = -277.2m USD
Long Term Debt = 85.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 13.7m USD (from shortTermDebt, last quarter)
Debt = 85.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -250.1m USD (from netDebt column, last quarter)
Enterprise Value = 3.81b USD (4.39b + Debt 85.7m - CCE 665.4m)
Interest Coverage Ratio = -954.1 (Ebit TTM -285.3m / Interest Expense TTM 299.0k)
FCF Yield = -6.63% (FCF TTM -252.9m / Enterprise Value 3.81b)
FCF Margin = -565.7% (FCF TTM -252.9m / Revenue TTM 44.7m)
Net Margin = -616.0% (Net Income TTM -275.4m / Revenue TTM 44.7m)
Gross Margin = 81.87% ((Revenue TTM 44.7m - Cost of Revenue TTM 8.11m) / Revenue TTM)
Gross Margin QoQ = 81.84% (prev 90.73%)
Tobins Q-Ratio = 3.37 (Enterprise Value 3.81b / Total Assets 1.13b)
Interest Expense / Debt = 0.13% (Interest Expense 108.0k / Debt 85.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -225.4m (EBIT -285.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.32 (Total Current Assets 728.3m / Total Current Liabilities 87.5m)
Debt / Equity = 0.09 (Debt 85.7m / totalStockholderEquity, last quarter 971.5m)
Debt / EBITDA = 0.90 (negative EBITDA) (Net Debt -250.1m / EBITDA -277.2m)
Debt / FCF = 0.99 (negative FCF - burning cash) (Net Debt -250.1m / FCF TTM -252.9m)
Total Stockholder Equity = 871.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.35% (Net Income -275.4m / Total Assets 1.13b)
RoE = -31.60% (Net Income TTM -275.4m / Total Stockholder Equity 871.6m)
RoCE = -29.80% (EBIT -285.3m / Capital Employed (Equity 871.6m + L.T.Debt 85.7m))
RoIC = -25.86% (negative operating profit) (NOPAT -225.4m / Invested Capital 871.6m)
WACC = 14.11% (E(4.39b)/V(4.48b) * Re(14.38%) + D(85.7m)/V(4.48b) * Rd(0.13%) * (1-Tc(0.21)))
Discount Rate = 14.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.25%
Fair Price DCF = unknown (Cash Flow -252.9m)
EPS Correlation: -32.06 | EPS CAGR: -34.10% | SUE: -0.87 | # QB: 0
Revenue Correlation: -1.35 | Revenue CAGR: 6.90% | SUE: -1.36 | # QB: 0

Additional Sources for KYMR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle